SSR-180,711

SSR-180,711‏‎ is a drug that acts as a potent and selective antagonist for the Alpha-7 nicotinic acetylcholine receptor. It has been researched for its potential therapeutic applications in the treatment of schizophrenia, cognitive deficits, and Alzheimer's disease.

Pharmacology

SSR-180,711‏‎ is a selective antagonist for the Alpha-7 nicotinic acetylcholine receptor. This receptor is a type of nicotinic acetylcholine receptor, which is a class of ionotropic receptors that respond to the neurotransmitter acetylcholine. The Alpha-7 receptor subtype is found in the brain and is thought to play a role in cognitive functions such as learning and memory.

Therapeutic Potential

SSR-180,711‏‎ has been investigated for its potential use in the treatment of several neurological and psychiatric disorders.

Schizophrenia

In preclinical studies, SSR-180,711‏‎ has shown promise as a potential treatment for schizophrenia. The drug appears to improve cognitive deficits associated with the disorder, which are not effectively treated by current antipsychotic medications.

Alzheimer's Disease

SSR-180,711‏‎ may also have potential in the treatment of Alzheimer's disease. The Alpha-7 nicotinic receptor is thought to play a role in the pathophysiology of Alzheimer's, and SSR-180,711‏‎'s ability to antagonize this receptor could potentially slow the progression of the disease.

See Also

• Alpha-7 nicotinic acetylcholine receptor
• Schizophrenia
• Alzheimer's disease

References

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian